Psyence BioMed welcomes U.S. action to speed ibogaine development
Psyence BioMed says it welcomes the U.S. administration’s latest action to accelerate ibogaine development.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.